We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Genetic Risk Factors Found in Gestational Diabetes

By LabMedica International staff writers
Posted on 26 Feb 2020
Gestational diabetes mellitus (GDM) is a common pregnancy complication affecting 6%–15% of pregnancies globally. More...
Although the condition resolves after delivery in most cases, women with a history of GDM have a more than sevenfold increased risk of developing type 2 diabetes (T2D) compared with women with a normoglycemic pregnancy.

Individual single nucleotide polymorphisms (SNPs) and genetic risk scores (GRSs) capturing the cumulative risk conferred by these SNPs have been associated with T2D risk in the general population. However, as women with a history of GDM already have an elevated baseline genetic risk for T2D compared with the general population. The role genetic factors play in the development of T2D among women with a history of GDM may differ from that in the general population.

A team of scientists at the at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Rockville, MD, USA) sought to gauge whether genetic risk scores could distinguish women with a history of gestational diabetes who develop T2D from those who do not. They applied this score to two population cohorts, one from the USA and one from Denmark, to find that women with high genetic risk scores were more likely to go on to develop T2D. Their findings also indicated that eating healthy could mitigate some of that risk.

Genotyping was performed using the TaqMan quantitative polymerase chain reaction (PCR) method (Applied Biosystems, Foster City, CA, USA) in 1,855 study participants from the USA and 603 from Denmark. In all, 112 candidate SNPs were selected based on previous genome- wide association studies (GWAS) of T2D. Genotyping was additionally performed using high- density SNP markers platforms, including, HumanHap, Infinium, OncoArray or Infinium HumanCoreExome (Illumina, San Diego, CA, USA).

Based on recent genome-wide association studies in European populations, the scientists identified 59 SNPs associated with T2D risk that they bundled into a genetic risk score for the condition. They then genotyped 2,434 white women with a history of gestational diabetes from the US Nurses' Health Study II and the Danish National Birth Cohort and determined their genetic risk scores. Of the women in the study, 601 developed T2D during the median follow-up period of 21 years for the US cohort and 13 years for the Danish cohort.

A high genetic risk score was associated with increased risk of developing T2D in both the US and Danish cohorts. When broken up by quartiles, the highest-scoring group was 19% more likely to develop T2D than the lowest scoring group. Every five risk alleles were associated with a 7% increase in T2D risk in the US cohort and 9% increase in risk in the Danish cohort.

The authors concluded that in a study based on two independent populations with a long follow- up period, they observed a significant association of genetic risk factors with the development of T2D. The magnitude of association, however, was modest. The study was published on February 13, 2020 in the journal BMJ Open Diabetes Research & Care.

Related Links:
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Applied Biosystems
Illumina



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.